This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Ride The Cannabis Legalization Wave With These 3 Stocks
by Tirthankar Chakraborty
Stocks like Cronos Group (CRON), Canopy Growth (CGC) and Innovative Industrial Properties (IIPR) are sure to benefit at present amid the cannabis legalization wave.
Do Options Traders Know Something About Canopy Growth (CGC) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to for Canopy Growth (CGC) stock based on the movements in the options market lately.
Canopy Growth Corporation (CGC) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Canopy Growth Corporation (CGC) closed at $9.27 in the latest trading session, marking a +1.31% move from the prior day.
Should You Buy Beaten Down Cannabis Stocks & ETFs Now?
by Neena Mishra
CNBC's cannabis expert Tim Seymour discusses the outlook for the industry.
Canopy Growth Corporation (CGC) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Canopy Growth Corporation (CGC) delivered earnings and revenue surprises of -178.57% and -6.23%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
What's in Store for Canopy Growth (CGC) in Q2 Earnings?
by Zacks Equity Research
Canopy Growth's (CGC) newly-added Ace Valley and Supreme Cannabis hold part of the company's market share in fiscal Q2.
Clover Health (CLOV) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
Clover Health's (CLOV) third-quarter results are likely to benefit from Direct Contracting and strategic partnerships.
Canopy Growth Corporation (CGC) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Canopy Growth Corporation (CGC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Humana (HUM) to Post Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Humana's (HUM) third-quarter earnings are expected to have gained from higher revenues and a solid contribution from its Retail and Healthcare Services segments.
Canopy Growth Corporation (CGC) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Canopy Growth Corporation (CGC) closed at $13.01, marking a +1.76% move from the previous day.
4 Medical Products Stocks Poised to Beat This Earnings Season
by Urmimala Biswas
Amid concerns surrounding growing COVID-19 cases affecting the medical products companies' legacy business, we are optimistic about IDXX, HSIC, CGC and PODD's results this time around.
AmerisourceBergen (ABC) to Post Q4 Earnings: What's in Store?
by Zacks Equity Research
AmerisourceBergen's (ABC) fiscal fourth-quarter results are likely to reflect solid performance at Pharmaceutical Distribution and Other units.
DENTSPLY SIRONA (XRAY) to Post Q3 Earnings: What's in Store?
by Zacks Equity Research
DENTSPLY SIRONA (XRAY) third-quarter results are likely to reflect strong segmental performance.
Conformis (CFMS) to Post Q3 Earnings: What's in the Offing?
by Zacks Equity Research
Conformis' (CFMS) third-quarter results are likely to reflect strength in core products.
PerkinElmer (PKI) to Post Q3 Earnings: What's in the Cards?
by Zacks Equity Research
PerkinElmer's (PKI) third-quarter results are likely to reflect strong performance at the Diagnostics segment.
McKesson (MCK) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
McKesson's (MCK) fiscal second-quarter results are likely to reflect the solid show by the U.S. Pharmaceutical and Specialty Solutions segment.
Cerner (CERN) to Report Q3 Earnings: What's in the Offing?
by Zacks Equity Research
Cerner's (CERN) third-quarter results are likely to reflect gains from strategic deals.
Stryker (SYK) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Stryker's (SYK) third-quarter results are likely to reflect strong segmental performances at Medsurg, Orthopaedic and Neurotechnology & Spine.
Baxter (BAX) to Report Q3 Earnings: What's in the Offing?
by Zacks Equity Research
Baxter's (BAX) third-quarter results are likely to reflect growth in its Acute Therapies business.
DexCom (DXCM) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
DexCom's (DXCM) third-quarter results are likely to reflect rising global awareness of its real-time CGM.
What's in Store for West Pharmaceutical's (WST) Q3 Earnings?
by Zacks Equity Research
West Pharmaceutical's (WST) third-quarter results are likely to reflect strength in the Proprietary Products business.
Canopy Growth Corporation (CGC) Moves 8.6% Higher: Will This Strength Last?
by Zacks Equity Research
Canopy Growth Corporation (CGC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Canopy Growth Corporation (CGC) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Canopy Growth Corporation (CGC) delivered earnings and revenue surprises of 27.78% and 3.95%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Canopy Growth Corporation (CGC) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Canopy Growth Corporation (CGC) closed at $18.80, marking a -0.58% move from the previous day.
Canopy Growth (CGC) to Report in Q1 Earnings: What's in Store?
by Zacks Equity Research
Continued robust product demand is expected to have significantly contributed to Canopy Growth's (CGC) top line in the fiscal first quarter.